Neurocrine Biosciences, Inc. · NASDAQ:NBIX
Neurocrine Biosciences — Q3 2022 Earnings Presentation
40 slides from Neurocrine Biosciences's earnings presentation, Nov 1, 2022
Slide 1: Advancing Life-Changing Discoveries in Neuroscience
Advancing Life-Changing Discoveries in Neuroscience Q3 2022 Corporate Presentation November 1, 2022 Nasdaq: NBIX
Slide 2: Safe Harbor Statement and Non-GAAP Financial Measures
Safe Harbor Statement and Non-GAAP Financial Measures In addition to historical facts, this presentation contains forward-looking statements that involve a number of risks and uncertainties. These statements include, but are not limited to, statements related to: the benefits to be derived from our
Slide 3: Well Positioned for Sustained & Long-term Growth
Well Positioned for Sustained & Long-term Growth * Raised 2022 Annual ~500,000 undiagnosed and untreated patients with Sales Guidance to Tardive Dyskinesia (TD) in the U.S. $1.4B to $1.425B Significant Opportunity for Growth R&D Focus Robust 12 Programs Currently in Mid-to-Late-Stage Studies • Neuro
Slide 4: Q3 2022 Highlights and Future Key Milestones and Activities
Q3 2022 Highlights and Future Key Milestones and Activities Q3 2022 Highlights Future Key Milestones and Activities ▪ INGREZZA® (valbenazine) Net Product Sales of ~$376 Million 2022 − Q3 2022 INGREZZA Net Sales and TRx Grew 31% and 32%, ▪ FY INGREZZA Net Sales Guidance Raised to $1.4 Billion to $1.4
Slide 5: Strong Pipeline Momentum
Strong Pipeline Momentum Phase 1 Phase 2 Phase 3 Partner Upcoming Milestones Neurology valbenazine* Chorea in Huntington Disease Submitted Supplemental New Drug Application valbenazine* Dyskinetic Cerebral Palsy Registrational Top-Line Data Expected in 2024 NBI-827104 Rare Pediatric Epilepsy: EE-CSW
Slide 6: Pipeline Features Novel Mechanisms to Treat Intractable Diseases
Pipeline Features Novel Mechanisms to Treat Intractable Diseases Focused on Neurology, Neuroendocrinology, and Neuropsychiatry Neurology Neuroendocrinology Epileptic SCN8A Encephalopathy Congenital Tardive Focal Onset Developmental Uterine with Continuous Endometriosis** Adrenal Dyskinesia* Seizures
Slide 7: Significant Clinical Progress Expected Through 2023
Significant Clinical Progress Expected Through 2023 Significant Milestones in 2H 2022 2023 Clinical Activities & Milestones Valbenazine in Chorea in Huntington Disease Valbenazine in Chorea in Huntington Disease Submitted sNDA with the FDA Potential sNDA Approval NBI-1117568 in Schizophrenia Crinece
Slide 8: Q3 2022 Financial Summary
Q3 2022 Financial Summary $ Millions, Except Non-GAAP Earnings Per Share Item Q3 2022 Q3 2021 Highlights / Comments Revenue $388 $296 Q3 2022 INGREZZA Sales of $376M with Record - Product Sales, Net 379 289 New Patients and Continued Strong Compliance / Persistence Rates for Existing Patients - Coll
Slide 9: 2022 INGREZZA Sales Guidance Raised and Operating Expense Guidance Reaffirmed
2022 INGREZZA Sales Guidance Raised and 2022 Operating Expense Guidance Reaffirmed 2021 2022 Previous 2022 Current Item ($ Millions) Comments Actuals Guidance Range Guidance Range INGREZZA Net Product Sales1 $1,082 $1,350 - $1,400 $1,400 - $1,425 Raising Net Sales Range GAAP R&D Expense2 $328 $415 -
Slide 10: Corporate Sustainability
Corporate Sustainability Our Purpose: Relieve Suffering for People with Great Needs, but Few Options Adhere to the highest Invest in our people Minimize our impact product quality and and communities on the environment safety standards Comprehensive Quality Industry-leading employee Improving profit
Slide 11: Our Medicines, Our Patients
© NEYROCRINE Our Medicines, Our Patients
Slide 12: INGREZZA Quarterly Net Sales Performance
INGREZZA Quarterly Net Sales Performance ($MM) $400 $376 6th Sequential $350 $350 Period of Growth $301 $303 $300 $287 $265 $250 $240 $230 $200 Q4 '20 Q1 '21 Q2 '21 Q3 '21 Q4 '21 Q1 '22 Q2 '22 Q3 '22 12
Slide 13: Substantial Impact on TD Patients and Care Partners
Substantial Impact on TD Patients and Care Partners Movement disorder caused by prolonged use of antipsychotics and anti-nausea medications Uncontrollable, abnormal and repetitive movements >50% of patients experience meaningful emotional, social and psychological impact* Job Performance Low Self-Wo
Slide 14: Nascent TD Market Presents Significant Opportunity
Nascent TD Market Presents Significant Opportunity Approximately 30% of TD Patients Diagnosed E S T I M AT E D T O A F F E C T ~600,000 ✓ Only half of diagnosed patients receive treatment for TD with a VMAT2 inhibitor like INGREZZA people in the U.S. ~30% TD Diagnosed Increasing Antipsychotic Prescr
Slide 15: Driving Long-Term Growth for INGREZZA
Driving Long-Term Growth for INGREZZA Salesforce and distribution expansion INGREZZA and ONGENTYS offering greater access to neurology practices Investing in telemedicine capabilities Recommends patients with TD associated with antipsychotic therapy be treated with a VMAT2 inhibitor Patient outreach
Slide 16: Submitted sNDA for Valbenazine for Chorea in Huntington Disease
Submitted Supplemental New Drug Application for Valbenazine for the Treatment of Chorea in Huntington Disease Valbenazine* Simple once-a-day treatment targeted for symptom control of chorea movements Safety profile consistent with and supported by extensive safety data in tardive dyskinesia In rando
Slide 17: Valbenazine: Registrational Programs in ATS and DCP
Valbenazine*: Registrational Programs in ATS and DCP Adjunctive Treatment of Schizophrenia (ATS) Dyskinetic Cerebral Palsy (DCP) Schizophrenia is one of the leading causes A form of cerebral palsy (CP) that affects of disability worldwide, affecting up to 3.5M ~15% of the approximately 500,000 to 1M
Slide 18: ONGENTYS Is the 1st and Only FDA-Approved Once-Daily COMT Inhibitor
ONGENTYS Is the 1st and Only FDA-Approved Once-Daily COMT Inhibitor for Parkinson’s Disease Provides Significant Reduction of Daily “Off” Time; Increase in Good “On” Time • Add-on treatment to levodopa/carbidopa prolongs clinical effects • One capsule, once a day treatment • Helps patients achieve m
Slide 19: Neurology Pipeline
© NEVROCRINE Neurology Pipeline
Slide 20: Potential First-in-Class Neurology Programs
Potential First-in-Class Neurology Programs Collaborations with Idorsia and Xenon Ongoing Clinical Programs in Phase 2 Studies Clinical Programs in Phase 2 Studies Top-line Data Expected by Year-End NBI-827104* Rare Pediatric Epilepsy: EE-CSWS in 2022 Focal Onset Seizures in Adults Top-line Data Exp
Slide 21: NBI-827104: Selective Cav Blocker
NBI-827104*: Selective Cav Blocker NBI-827104 Investigational, potent, selective, orally active and brain penetrating T-type calcium channel blocker (Cav 3.1, Cav 3.2, Cav 3.3) with 1x/day dosing Program has potential to address other central nervous system diseases EE-CSWS Background EE-CSWS Progra
Slide 22: NBI-921352: Selective Nav1.6 Inhibitor in Ongoing Phase 2 Studies
NBI-921352*: Selective Nav 1.6 Inhibitor in Ongoing Phase 2 Studies Adult Focal Onset Seizures Background SCN8A-DEE Background Also referred to as partial-onset seizures, Rare pediatric epilepsy with occurrence of these are the most common form of seizures seizures beginning in the first 18 months o
Slide 23: Neuroendocrinology Pipeline
Neuroendocrinology Pipeline
Slide 24: Classic Congenital Adrenal Hyperplasia (CAH)
Classic Congenital Adrenal Hyperplasia (CAH) Rare Genetic Disorder Enzyme deficiency & reduced cortisol levels and excess androgen levels U.S. ~30,000* Europe ~50,000* Complex and Treatment Options Highly Stagnant for 60 Years Variable • Hormone replacement Symptoms • Do not address underlying issue
Slide 25: Congenital Adrenal Hyperplasia Disease Mechanism
Congenital Adrenal Hyperplasia Disease Mechanism Normal Homeostasis CAH Patients 25
Slide 26: Crinecerfont Potentially Meets Challenges of the Standard of Care
Crinecerfont* Potentially Meets Challenges of the Standard of Care Overtreatment Hypercortisolism Overtreatment Insulin Resistance Undertreatment Hypercortisolism Central Obesity Hyperandrogenism Osteoporosis Potentially Fatal Adrenal Crisis Insulin Resistance Impaired Glucose Tolerance CRINECERFONT
Slide 27: Potential Paradigm Shift in the Treatment of CAH
Potential Paradigm Shift in the Treatment of CAH Crinecerfont* Phase 3 Global Adult Registrational Study Ongoing Top-Line Results Phase 3 Global Pediatric Registrational Study Ongoing Expected in 2023 Potent Orally Active Selective Well-Tolerated *Crinecerfont is investigational and not approved in
Slide 28: Neuropsychiatry Pipeline
(5) NEUROCRINE BIOSCIENCES
Slide 29: Potential First-in-Class Neuropsychiatry Programs
Potential First-in-Class Neuropsychiatry Programs Takeda Collaborations Ongoing Clinical Programs in Phase 2 Studies Clinical Programs in Phase 2 Studies NBI-1065846* Anhedonia in Major Depressive Disorder Top-line Data Expected in 2023 Inadequate Response to Treatment in NBI-1065845* Major Depressi
Slide 30: NBI-1065846: GPR139 Agonist
NBI-1065846*: GPR139 Agonist Anhedonia in Major Depressive Disorder NBI-1065846 260 million+ people worldwide are Potent first-in-class investigational GPR139 agonist • Once weekly affected by major depressive disorder • Potential adjunctive treatment (MDD). GPR139 is an orphan receptor in the haben
Slide 31: NBI-1065845: AMPA Potentiator
NBI-1065845*: AMPA Potentiator Inadequate Response to Treatment NBI-1065845 in Major Depressive Disorder (MDD) Potent first-in-class AMPA potentiator ~1/3 of the 16 million+ people in the • Once daily U.S. who live with MDD do not respond • Potential adjunctive treatment to available antidepressants
Slide 32: Luvadaxistat: D-Amino Acid Oxidase (DAAO) Inhibitor
Luvadaxistat*: D-Amino Acid Oxidase (DAAO) Inhibitor Cognitive Impairment Associated with Luvadaxistat Schizophrenia (CIAS) Affects approximately 80% of the 3.5 Potent first-in-class DAAO inhibitor • Once daily million people in the U.S. diagnosed • No titration requirement with schizophrenia Hypofu
Slide 33: Developing Novel Muscarinic Receptor Agonist Portfolio
Developing Novel Muscarinic Receptor Agonist Portfolio Neurocrine Biosciences Advancing Muscarinic Portfolio Clinical studies, include: ➢ Initiated Phase 2 placebo-controlled study of NBI-1117568*, a selective M4 agonist, as a potential treatment for schizophrenia ✓ NBI-1117568 offers the potential
Slide 34: Well Positioned for Sustained & Long-term Growth
Well Positioned for Sustained & Long-term Growth * Raised 2022 Annual ~500,000 undiagnosed and untreated patients with Sales Guidance to Tardive Dyskinesia (TD) in the U.S. $1.4B to $1.425B Significant Opportunity for Growth R&D Focus Robust 12 Programs Currently in Mid-to-Late-Stage Studies • Neuro
Slide 35: GAAP to Non-GAAP Reconciliations
GAAP to Non-GAAP Reconciliations neurocrine.com
Slide 36: Condensed Consolidated Statements of Income
NEUROCRINE BIOSCIENCES NEUROCRINE BIOSCIENCES, INC. CONDENSED CONSOLIDATED STATEMENTS OF INCOME (in millions, except per share data) Revenues: Product sales, net Collaboration revenue Total revenues Operating expenses: Cost of revenues Research and development Acquired in-process research and develo
Slide 37: Condensed Consolidated Balance Sheets
NEUROCRINE BIOSCIENCES CONDENSED CONSOLIDATED BALANCE SHEETS (in millions) NEUROCRINE BIOSCIENCES, INC. (unaudited) Cash, cash equivalents and debt securities available-for-sale Other current assets Total current assets Deferred tax assets Debt securities available-for-sale Right-of-use assets Prope
Slide 38: Reconciliation of GAAP to Non-GAAP Financial Results
NEUROCRINE BIOSCIENCES NEUROCRINE BIOSCIENCES, INC. RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL RESULTS (in millions, except per share data) GAAP net income Adjustments: Stock-based compensation expense - R&D Stock-based compensation expense - SG&A Loss on extinguishment of convertible senior notes
Slide 39: Reconciliation of GAAP to Non-GAAP Expenses
NEUROCRINE BIOSCIENCES RECONCILIATION OF GAAP TO NON-GAAP EXPENSES (in millions) GAAP R&D Adjustments: Stock-based compensation expense Non-GAAP R&D GAAP SG&A Adjustments: Stock-based compensation expense Non-GAAP SG&A NEUROCRINE BIOSCIENCES, INC. (unaudited) Three Months Ended Nine Months Ended Sep
Slide 40: Advancing Life-Changing Discoveries in Neuroscience
Advancing Life-Changing Discoveries in Neuroscience Q3 2022 Corporate Presentation November 1, 2022 Nasdaq: NBIX
Neurocrine Biosciences — Q3 2022 Earnings Presentation on 6ix